34 documents

Read All
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
Read More
22:58 , Apr 25, 2019 |  BC Innovations  |  Emerging Company Profile

Cell Mogrify directly reprograms cells in vivo

Mogrify is jumping ahead of the technologies that have propelled the stem cell field by creating a platform that bypasses intermediate steps, and opens the door to in vivo reprogramming. Cell Mogrify Ltd. uses small...
Read More
22:46 , Apr 16, 2019 |  BC Extra  |  Preclinical News

Mounting a mitochondrial attack to starve the inflammasome

While companies are directly inhibiting NLRP3 to treat a swath of inflammatory diseases, at least one academic group is shutting down the protein’s upstream mitochondrial triggers. The approach, from University of California San Diego researchers,...
Read More
17:44 , Nov 16, 2018 |  BC Week In Review  |  Company News

AbbVie strengthens early stage neurology focus with Mission deal

Mission Therapeutics Ltd. (Cambridge, U.K.) and AbbVie Inc. (NYSE:ABBV) partnered to develop deubiquitinase inhibitors for Alzheimer's and Parkinson's diseases. The deal is the second in as many weeks for AbbVie for early stage neurology candidates....
Read More
15:24 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer Patient sample, cell culture and mouse studies suggest inhibiting USP7 could help treat cervical cancer. In cervical samples from 20 patients, levels of USP7 mRNA were higher than in samples from healthy...
Read More
17:57 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Winter, Jackson, Ramakishnan, Balasubramaniam among co-founders of new U.K. fund Ahren

Ahren Innovation Capital LLP (Cambridge, U.K.) announced the first close of its Ahren LP fund with over $100 million from Aviva, Wittington Investments and undisclosed U.S. family offices. The fund declined to disclose the exact...
Read More
23:29 , Sep 4, 2018 |  BC Extra  |  Financial News

Winter, Jackson, Ramakishnan, Balasubramaniam among co-founders of new U.K. fund Ahren

Ahren Innovation Capital LLP (Cambridge, U.K.) announced the first close of its Ahren LP fund with over $100 million from Aviva, Wittington Investments and undisclosed U.S. family offices. The fund declined to disclose the exact...
Read More
16:14 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest inhibiting USP7 could help treat metastases of melanoma. In 114 melanoma patients, high primary tumor levels of USP7 correlated with poor survival, and in eight xenograft mouse...
Read More
22:00 , Jun 18, 2018 |  BC Extra  |  Company News

Management tracks: Ionis, Albireo

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) hired Damien McDevitt as CBO. He was SVP of corporate development at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD). Hepatic disease company Albireo Pharma Inc. (NASDAQ:ALBO) hired Jason Duncan as general counsel. He was...
Read More
15:32 , Jun 8, 2018 |  BioCentury  |  Finance

Pfizer plugs back in

While Pfizer Inc. (NYSE:PFE) retreated from neuroscience R&D in January, the pharma hasn’t cut the cord yet. Ramped up allocations to neuroscience out of its latest $600 million venture investment give Pfizer the ability to...
Read More